Lisata Therapeutics Completes Enrollment for Cancer Therapy Trial
By Karen Roman
Biopharma company Lisata Therapeutics, Inc. (Nasdaq: LSTA) said it finished patient enrollment for the next stage of its CENDIFOX trial.
The study will assess the safety and effects of combining certepetide, Lisata’s cyclic peptide candidate, with FOLFIRINOX-based therapies for pancreatic, colon, and appendiceal cancers, it stated.
“By addressing the unmet medical needs of patients with solid tumors, we aim to improve patient outcomes and augment the standard-of-care paradigm,” said Kristen K. Buck, Lisata’s EVP of Research and Development and Chief Medical Officer.
Exec Edge
Editor@Executives-edge.com
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10